Moderna Cancer Vaccine Reduces Melanoma Recurrence in Phase 3 Trial
Moderna reported that its personalized mRNA cancer vaccine significantly reduces melanoma recurrence when combined with Merck's Keytruda, driving the company's market capitalization to $82 billion.
Moderna reported positive Phase 3 clinical trial data for intismeran autogene, a personalized mRNA-based cancer vaccine developed in partnership with Merck Group. The trial found that the vaccine, when used as a combination therapy with the cancer drug Keytruda, significantly reduced the risk of melanoma recurrence, marking the first such success for personalized cancer vaccines.
This clinical milestone contributed to a surge in the company's share price throughout 2026, pushing Moderna's market capitalization to $82 billion. The company also recently earned approval for its influenza vaccine, mFLUSIVA.
While some analysts suggest intismeran autogene could eventually generate over $10 billion in peak revenue, other financial perspectives argue the current valuation is too high because the cancer vaccine has not yet received regulatory approval.